Binding of Recombinant Human Cytokeratin 19 to Laminin
Total Page:16
File Type:pdf, Size:1020Kb
CELL STRUCTURE AND FUNCTION 25: 171–175 (2000) © 2000 by Japan Society for Cell Biology Binding of Recombinant Human Cytokeratin 19 to Laminin: A Possible Role in Interaction between Intermediate Filament Derived from Epithelial Cells and Extracellular Matrixes Naomi Dobashi1, Jiro Fujita1,*, Masayuki Murota2, Yuji Ohtsuki3, Shuji Bandoh1, Yutaka Ueda1, Kazutaka Dohmoto1, Satoko Hojo1, Mikio Nishioka2, Toshihiko Ishida, and Jiro Takahara1 1First Department of Internal Medicine, Kagawa Medical University, Kagawa 2Third Department of Internal Medicine, Kagawa Medical University, Kagawa 3Department of Pathology, Kochi Medical School, Kochi, Japan ABSTRACT. Cytokeratin 8 (CK8) and cytokeratin 19 (CK19) is a specific cytoskeletal component of simple epi- thelia, including bronchial epithelial cells. We hypothesized that CK8 or CK19 released from epithelial cells may bind to and cause damage to extracellular matrixes through binding of anti-CK8 or anti-CK19 autoantibodies. In the present study, bindings of recombinant human CK8 and CK19 to laminin (both derived from mouse sarcoma cells and human), collagen, gelatin, and fibronectin were evaluated by a modified enzyme-linked immunosorbent assay (ELISA). In addition, binding of CK19 to laminin was also confirmed by inhibition assay. As a result, CK19 strongly bound to mouse laminin as well as human laminin. Pretreatment with laminin significantly reduced the binding of CK19 to laminin. However, binding of recombinant CK19 to laminin was not demonstrated by Western immunoblot, suggesting that SDS treatment of laminin diminished the binding. These results suggest that released CK19 from epithelial cells may have played a role in the damage of basement membrane by accumulation of an immune complex composed by CK19 and anti-CK19 autoantibody. Key words: cytokeratin 8/cytokeratin 19/laminin/extracellular matrix/epithelial cells Cytokeratins (Cks) are a multigene family of polypeptides the aid of monoclonal antibodies in patients with lung can- which form the cytoskeleton of epithelial cells. On the basis cer (Pujol et al., 1993). In addition, a CYFRA 21-1 assay of differences in molecular weight and pH, at least 20 differ- has been developed. Combines 2 monoclonal antibodies di- ent types of CKs have been identified. These are expressed rected specifically against the degradation product of CK19 in certain sets along various routes of epithelial differentia- (Pujol et al., 1993). Clinical investigations have suggested tion in normal epithelium, tumor cells, and culture cells that serum CYFRA 21-1 is one of the most important tumor (Moll et al., 1982; Fuchs, 1988; Coulombe, 1993; Steinert, markers in the follow-up of non-small cell lung cancer, es- 1993). Cytokeratin 8 (CK8) and cytokeratin 19 (CK19) are pecially squamous cell lung cancer (Pujol et al., 1993). Fur- specific cytoskeletal structures of simple epithelia, includ- thermore, we have previously demonstrated that anti-CK8 ing bronchial epithelial cells (Moll et al., 1982; Fuchs, 1988; and anti-CK19 autoantibodies are formed in patients with Coulombe, 1993; Steinert, 1993). Although the precise idiopathic pulmonary fibrosis (Dobashi et al., 1998; Fujita mechanism of their generation remains unknown, fragments et al., 1999). of cytokeratin are soluble in serum and can be detected with In this study, we hypothesized that recombinant CK8 or recombinant CK19 may bind to extracellular matrixes and we demonstrate new evidence that recombinant CK19 has * To whom correspondence should be addressed: Jiro Fujita, M.D., First the ability to interact with the major basement membrane Department of Internal Medicine, Kagawa Medical University, 1750-1, protein, laminin. Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. Tel: +81-87-891-2145, Fax: +81-87-891-2147 E-mail: [email protected] Abbreviations: CK8, cytokeratin 8; CK19, cytokeratin 19; ELISA, enzyme-linked immunosorbent assay; CKs, cytokeratins; SDS, sodium dodecyl sulfate. 171 N. Dobashi et al. Materials and Methods Germany) was incubated in wells for 60 min. After washing the plate, bound CK8 or CK19 was incubated with mouse monoclonal anti-human CK8 (clone 18.7, Progen Biotechnik GMBH, Binding of cytokeratin 19 to laminin, collagen, gelatin Heidelberg, Germany, at 1:1000 dilution) or with mouse mono- and fibronectin clonal anti-human CK19 (clone 19.2, Progen Biotechnik GMBH, Tests for binding of CK8 or CK19 to various extracellular matrixes Heidelberg, Germany, at 1:1000 dilution). After incubation and were performed using modified enzyme-linked immunosorbent washing, the solid phase-bound mouse monoclonal anti-human assays (ELISA). For binding assays, polystyrene microtiter plates CK8 or CK19 antibody was further incubated with peroxidase- (ELISA plates, Cooke Laboratory Products Div., Dynatech conjugated goat anti-mouse IgG antibody (Sigma ImmunoChemi- Laboratories Inc., Alexandria, VA, USA) were coated with various cals, lot 38H4856, St Louis, MO, USA, diluted 1:1000) for 60 min. concentrations of mouse laminin (from basement membrane of After further washes, TMB Peroxidase EIA Substrate Kit (Bio- Engelbreth-Holm-Swarm Mouse sarcoma, lot 79H4000, Sigma Rad Laboratories, Hercules, CA, USA) was used to measure Chemical Co., St Louis, MO, USA), human laminin (derived from the amount of solid phase-bound antibodies. All incubations were human placenta, purified by immunoaffinity from pepsinized performed at room temperature. Data were expressed as placenta, lot 19H4052, Sigma Chemical Co.), collagen (Type I, mean±standard deviation from triplicate determinations. derived from calf skin, lot 87H2303, Sigma Chemical Co.), gelatin (Bio-Rad Laboratories, Hercules, CA, USA), and fibronectin (de- Avidity of binding of cytokeratin 19 to extracellular rived from human plasma, lot 38683, CAPPELTM Reseach Prod- matrix ucts, Durham, NC, USA). The purity of laminin was checked The binding of CK19 to extracellular matrixes was further charac- by Coomassie blue staining of a sodium dodecyl sulfate (SDS)- terized by testing the capacity of the extracellular matrixes to polyacrylamide gel. inhibit binding of CK19 to laminin. For inhibition assays, the After washing, commercially available recombinant human microtiter plate wells were coated with 0.5 mg/ml of laminin. CK8 (Progen Biotechnik GMBH, lot 65138, Heidelberg, Germa- Recombinant human CK19 was preincubated with several concen- ny) or CK19 (Progen Biotechnik GMBH, lot 503209, Heidelberg, Fig. 1. Binding of human recombinant cytokeratin 8 and cytokeratin 19 to mouse laminin (A, B) and human laminin (C, D). Left bars represent the pres- ence of recombinant cytokeratin 8 (A, C) or cytokeratin 19 (B, D) and right bars represent the absence of recombinant cytokeratin 19 (negative control). Cytokeratin 8 does not bind to mouse laminin (A) or human laminin (C). In contrast, human recombinant cytokeratin 19 binds to mouse laminin (B) as well as human laminin (D). 172 Binding of Cytokeratin 19 to Laminin 19.2, at 1:1000 dilution) and peroxidase conjugated goat anti- mouse IgG antibody (Sigma ImmunoChemicals, lot 38H4856, St. Louis, MO, USA), and stained with 4CN PLUS for chromogenic detection of horse radish peroxidase (NEMTM Life Science Prod- ucts, Boston, MA, USA). In addition, recombinant human CK19, recombinant human CK8, and albumin were transferred to nitrocellulose membrane and incubated with mouse laminin (2 mg/ ml) for 60 min. Mouse laminin was then detected by immunoblot- ting using rabbit anti-mouse laminin antibody (LSL Co., Ltd., Tokyo, Japan, lot 832011, at 1:100 dilution) and peroxidase conju- gated goat anti-rabbit IgG antibody (Sigma ImmunoChemicals, lot 68H4875, St Louis, MO, USA), and stained with 4CN PLUS for chromogenic detection of horse radish peroxidase (NEMTM Life Science Products, Boston, MA, USA). Results Human recombinant CK19 bound dose dependently to mouse laminin (Fig. 1B). In addition, human recombinant CK19 bound dose dependently to human laminin (Fig. 1D). In contrast, cytokeratin 8 did not bind to mouse laminin or Fig. 2. Binding of human recombinant cytokeratin 8 (A) and cytokeratin 19 (B) to collagen. Left bars represent the presence of recombinant cytokeratin 8 (A, C) or cytokeratin 19 (B, D) and right bars represent the absence of recombinant cytokeratins (negative control). Human recombi- nant cytokeratin 19 slightly binds to collagen. In contrast, cytokeratin 8 does not bind to collagen. trations of laminin, and the amount of cytokeratin 19 bound to the wells was detected with enzyme conjugated antibodies as de- scribed above. Data were expressed as mean±standard deviation from triplicate determinations, and results were given as a percent- age of inhibition. SDS-PAGE electrophoresis and Western blotting SDS-polyacrylamide gel electrophoresis was performed according to Laemmli’s method (Laemmli, 1970) with a slight modification. Commercially available laminin was mixed with SDS (2.0%) and heated (100°C, 5 min). The samples were then applied to a 10/20% SDS polyacrylamide gel, electrophoresed (60 mA, 120 min.), fixed in 50% methanol, 10% acetic acid, and stained with Coomassie Blue. Proteins were then electrophoretically transferred onto Fig. 3. Binding of human recombinant cytokeratin 8 (A) and cytokeratin nitrocellulose membrane by the method described previously 19 (B) to fibronectin. Left bars represent the presence of recombinant et al (Towbin ., 1979). Laminin transferred to nitrocellulose mem- cytokeratin 19 and right bars represent the absence of recombinant brane was incubated with recombinant human CK19 (2